Repository logo
 
Publication

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Adults in Portugal Versus "No Vaccination" and Versus Vaccination with the 23-Valent Pneumococcal Polysaccharide Vaccine

2019Journal article Open access
Simple item page
dc.contributor.authorGouveia, M
dc.contributor.authorJesus, G
dc.contributor.authorInês, M
dc.contributor.authorCosta, J
dc.contributor.authorBorges, M
dc.date.accessioned2021-04-21T14:23:42Z
dc.date.available2021-04-21T14:23:42Z
dc.date.issued2019
dc.description.abstractThe burden of pneumococcal disease in adults is substantial from a social and economic point of view. This study assessed the cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23). A Markov model was used to simulate three strategies: no vaccination, complete vaccination with PPSV23 and complete vaccination with PCV13. The comparison between strategies allowed the estimation of clinical and economic outcomes including incremental cost-effectiveness ratios (ICER) and incremental cost-utility ratios (ICUR). The model took into account the distributions of age, risk profile, vaccination status, type of immunization and time since vaccination in the population. A societal perspective was adopted and a lifetime horizon was considered. Different sources of data and assumptions were used to calibrate PPSV23 and PCV13 effectiveness. Inpatient costs were based on the 2013 diagnosis-related group (DRG) database for National Health Service (NHS) hospitals and expert opinion; NHS official tariffs were the main source for unitary costs. PCV13 shows ICURs of €17,746/QALY and €13,146/QALY versus "no vaccination" and vaccination with PPSV23, respectively. Results proved to be robust in univariate sensitivity analyses, where all ratios were below a €20,000 threshold, with the exception of the scenario with PCV13 effectiveness halved. In a probabilistic sensitivity analysis, 94% of simulations showed cost-effectiveness ratios lower than €20,000/QALY, in both strategies. It was found that PCV13 is a cost-effective strategy to prevent pneumococcal disease in adults in Portugal.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationHum Vaccin Immunother. 2019;15(4):850-858.pt_PT
dc.identifier.doi10.1080/21645515.2018.1560769pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3666
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherTaylor & Francispt_PT
dc.subjectAdolescentpt_PT
dc.subjectAdultpt_PT
dc.subjectAgedpt_PT
dc.subjectAged, 80 and overpt_PT
dc.subjectHumanspt_PT
dc.subjectMiddle Agedpt_PT
dc.subjectPneumococcal Infectionspt_PT
dc.subjectPneumococcal Vaccinespt_PT
dc.subjectPortugalpt_PT
dc.subjectQuality-Adjusted Life Yearspt_PT
dc.subjectVaccinationpt_PT
dc.subjectVaccines, Conjugatept_PT
dc.subjectYoung Adultpt_PT
dc.subjectCost-Benefit Analysispt_PT
dc.subjectCHLC FARpt_PT
dc.titleCost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Adults in Portugal Versus "No Vaccination" and Versus Vaccination with the 23-Valent Pneumococcal Polysaccharide Vaccinept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage858pt_PT
oaire.citation.issue4pt_PT
oaire.citation.startPage850pt_PT
oaire.citation.titleHuman Vaccines & Immunotherapeuticspt_PT
oaire.citation.volume15pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hum Vacc Immunother.pdf
Size:
732.31 KB
Format:
Adobe Portable Document Format
Download

Collections

FAR - Artigos